본문으로 건너뛰기
← 뒤로

The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial.

무작위 임상시험 1/5 보강
Medicine 📖 저널 OA 98.4% 2021: 23/23 OA 2022: 25/25 OA 2023: 59/59 OA 2024: 58/58 OA 2025: 274/285 OA 2026: 186/186 OA 2021~2026 2025 Vol.104(18) p. e42284
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
40 patients in each group.
I · Intervention 중재 / 시술
an intravenous injection of esketamine (0
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Intravenous injection of 0.5 mg/kg esketamine during the induction period of general anesthesia can prevent and alleviate postoperative anxiety and depression in patients with thyroid cancer, and its mechanism may be related to increased mBDNF and 5-HT levels and reduced IGF-1 levels. At the same time, hemodynamics during anesthesia surgery are more stable.

Bi X, Dai J, Li J

📝 환자 설명용 한 줄

[BACKGROUND] This study aimed to investigate the effects of a single intravenous injection of esketamine during general anesthesia on postoperative anxiety and depression in patients with thyroid canc

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < .05

이 논문을 인용하기

↓ .bib ↓ .ris
APA Bi X, Dai J, Li J (2025). The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial.. Medicine, 104(18), e42284. https://doi.org/10.1097/MD.0000000000042284
MLA Bi X, et al.. "The effect of esketamine on postoperative anxiety and depression in patients with thyroid cancer: A randomized, double-blind, placebo-controlled, parallel-group trial.." Medicine, vol. 104, no. 18, 2025, pp. e42284.
PMID 40324271 ↗

Abstract

[BACKGROUND] This study aimed to investigate the effects of a single intravenous injection of esketamine during general anesthesia on postoperative anxiety and depression in patients with thyroid cancer.

[METHODS] In this randomized, double-blind, placebo-controlled, parallel-group trial, eighty female patients with thyroid cancer were scheduled to undergo surgery under general anesthesia. The patients were randomly divided into an esketamine group (group E) and a control group (group C), with 40 patients in each group. During the induction period of general anesthesia, group E received an intravenous injection of esketamine (0.5 mg/kg), while group C received an intravenous injection of 0.9% sodium chloride. The Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale scores for all patients were evaluated on the day before surgery and the second day after surgery. At the same time point, venous blood was collected twice from all patients, and the levels of serum factors, such as mature brain-derived neurotrophic factor (mBDNF), 5-hydroxytryptamine (5-HT), insulin-like growth factor-1 (IGF-1), and irisin, were measured. Intraoperative vital signs and general situation were recorded for all patients.

[RESULTS] Compared with group C, group E showed a significant decrease in postoperative anxiety and depression scores (P < .05). Compared with group C, group E showed a significant increase in postoperative mBDNF and 5-HT levels (P < .05), and the postoperative IGF-1 level in group E was significantly lower (P < .05). Compared with group C, the proportion of patients in group E who received pump infusion of vasopressors during surgery was significantly reduced (P < .05).

[CONCLUSION] Intravenous injection of 0.5 mg/kg esketamine during the induction period of general anesthesia can prevent and alleviate postoperative anxiety and depression in patients with thyroid cancer, and its mechanism may be related to increased mBDNF and 5-HT levels and reduced IGF-1 levels. At the same time, hemodynamics during anesthesia surgery are more stable.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (3)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기